医学临床研究
  2025年7月25日 星期五           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2024, Vol. 41 Issue (3): 356-359    DOI: 10.3969/j.issn.1671-7171.2024.03.010
  论著 本期目录 | 过刊浏览 | 高级检索 |
纤维蛋白原与前白蛋白比值、血红蛋白与红细胞分布宽度比与结直肠癌患者预后的关系
何捷
郑州市中医院检验科,河南 郑州 450000
Relationship between Fibrinogen to Prealbumin Ratio, Hemoglobin to Red Blood Cell Distribution Width Ratio and Prognosis of Colorectal Cancer Patients
HE Jie
Department of Laboratory Medicine, Zhengzhou Traditional Chinese Medicine Hospital, Henan Zhengzhou 450000
全文: PDF (1313 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨纤维蛋白原与前白蛋白比值(FPR)、血红蛋白与红细胞分布宽度比(HRR)与结直肠癌患者预后的关系。【方法】对92例行手术治疗的结直肠癌患者术后随访3年,根据预后结局将其分为预后良好组(无复发、转移或死亡)和预后不良组(复发、转移或死亡)。比较两组患者的临床资料及FPR、HRR,分析影响患者预后的因素;采用受试者工作特征(ROC)曲线分析FPR、HRR对患者预后的预测效能。【结果】结直肠癌患者术后3年内预后不良发生率为22.83%(21/92)。预后不良组FPR高于预后良好组,HRR低于预后良好组(P<0.05)。ROC曲线显示,FPR、HRR及二者联合预测患者预后的敏感度分别为76.20%、57.10%、90.50%,特异性分别为77.50%、69.00%、88.70%,曲线下面积(AUC)分别为0.804、0.722、0.899。预后不良组低分化占比、TNM分期Ⅲa期占比高于预后良好组(P<0.05);两组性别、年龄、肿瘤最大直径、肿瘤位置、病理类型等比较,差异均无统计学意义(P>0.05)。Cox多因素分析结果显示,TNM分期Ⅲa期、FPR高水平是患者预后的危险因素,HRR高水平是患者预后的保护因素(P<0.05)。高FPR患者与低FPR患者生存曲线比较,差异有统计学意义(P<0.05)。低HRR与高HRR患者生存曲线比较,差异有统计学意义(P<0.05)。【结论】检测结直肠癌患者FPR、HRR可用于预测患者的预后,且二者联合预测价值更好。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
何捷
关键词 结直肠肿瘤纤维蛋白原前白蛋白血红蛋白类红细胞指数    
Abstract:【Objective】To investigate the relationship between fibrinogen to prealbumin ratio(FPR), hemoglobin to red blood cell distribution width ratio(HRR) and prognosis of colorectal cancer patients. 【Methods】A total of 92 patients with colorectal cancer who underwent surgery were followed up for 3 years. According to the prognosis, they were divided into good prognosis group(no recurrence, metastasis or death) and poor prognosis group(recurrence, metastasis or death). The clinical data, FPR and HRR levels of the two groups were compared, and the factors affecting the prognosis of the patients were analyzed; Receiver operating characteristic(ROC) curve was used to analyze the predictive efficacy of FPR and HRR levels on the prognosis of patients. 【Results】 The incidence of poor prognosis in colorectal cancer patients within 3 years after operation was 22.83%(21/92). The FPR level in the poor prognosis group was higher than that in the good prognosis group, and the HRR level was lower than that in the good prognosis group(P<0.05). ROC curve showed that the sensitivity of FPR, HRR and their combination to predict the prognosis of patients were 76.20%, 57.10% and 90.50%, respectively, and the specificity was 77.50%, 69.00% and 88.70%, respectively. The area under the curve(AUC) was 0.804, 0.722 and 0.899, respectively. The proportion of poorly differentiated and TNM stage Ⅲa in the poor prognosis group was higher than that in the good prognosis group(P<0.05); There was no significant difference in gender, age, maximum diameter of tumor, tumor location, pathological type between the two groups(P>0.05). Cox multivariate analysis showed that TNM stage Ⅲa and FPR were risk factors for the prognosis of patients, while HRR was a protective factor for the prognosis of patients(P<0.05). The survival curve of patients with high FPR level was significantly different from that of patients with low FPR level(P<0.05). The survival curve of patients with low HRR level was significantly different from that of patients with high HRR level(P<0.05). 【Conclusion】The detection of FPR and HRR levels in patients with colorectal cancer can be used to predict the prognosis of patients, and the combined predictive value of the two is better.
Key wordsColorectal Neoplasms    Fibrinogen    Prealbumin    Hemoglobins    Erythrocyte Indices
收稿日期: 2023-07-06     
中图分类号:  R735.35  
引用本文:   
何捷. 纤维蛋白原与前白蛋白比值、血红蛋白与红细胞分布宽度比与结直肠癌患者预后的关系[J]. 医学临床研究, 2024, 41(3): 356-359.
HE Jie. Relationship between Fibrinogen to Prealbumin Ratio, Hemoglobin to Red Blood Cell Distribution Width Ratio and Prognosis of Colorectal Cancer Patients. JOURNAL OF CLINICAL RESEARCH, 2024, 41(3): 356-359.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.03.010     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I3/356
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn